Bago et al. reported that AKT inhibitors increased the activation of SGK3 in the treatment of breast cancer, and SGK3 replaces AKT by phosphorylated TSC2, leading to the failure of AKT inhibitor treatment in some breast cancer patients39. Here, TSC2 is linked to breast carcinoma.